Celgene Corporation (CELG) Holdings Reduced by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lowered its holdings in Celgene Corporation (NASDAQ:CELG) by 10.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 224,870 shares of the biopharmaceutical company’s stock after selling 25,373 shares during the quarter. Celgene Corporation accounts for about 0.7% of Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings, making the stock its 29th biggest position. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Celgene Corporation were worth $29,204,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in CELG. Harbour Capital Advisors LLC lifted its holdings in Celgene Corporation by 12,913.6% in the second quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after acquiring an additional 1,575,074 shares during the period. Investec Asset Management LTD acquired a new stake in Celgene Corporation in the first quarter valued at $194,490,000. Clearbridge Investments LLC lifted its holdings in Celgene Corporation by 24.1% in the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after acquiring an additional 892,392 shares during the period. State Street Corp lifted its holdings in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares during the period. Finally, Pioneer Investment Management Inc. lifted its holdings in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after acquiring an additional 710,584 shares during the period. 79.36% of the stock is owned by institutional investors.

In other news, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,233 shares of company stock worth $6,268,259. 0.95% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/11/celgene-corporation-celg-holdings-reduced-by-mitsubishi-ufj-kokusai-asset-management-co-ltd.html.

Shares of Celgene Corporation (NASDAQ:CELG) opened at 139.69 on Wednesday. The stock’s 50 day moving average price is $139.99 and its 200-day moving average price is $129.85. The stock has a market cap of $109.29 billion, a PE ratio of 43.26 and a beta of 1.88. Celgene Corporation has a one year low of $96.93 and a one year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.44 EPS. On average, equities analysts predict that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

A number of equities research analysts have commented on the company. Vetr raised Celgene Corporation from a “hold” rating to a “buy” rating and set a $146.58 target price for the company in a report on Friday, October 6th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $173.00 price target on shares of Celgene Corporation in a research note on Thursday, October 5th. Morgan Stanley downgraded Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research note on Thursday, October 5th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price target on shares of Celgene Corporation in a research note on Tuesday, September 26th. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $162.00 price target on shares of Celgene Corporation in a research note on Thursday, September 21st. Two equities research analysts

A number of other institutional investors have also added to or reduced their stakes in CELG. Harbour Capital Advisors LLC lifted its holdings in Celgene Corporation by 12,913.6% in the second quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after acquiring an additional 1,575,074 shares during the period. Investec Asset Management LTD acquired a new stake in Celgene Corporation in the first quarter valued at $194,490,000. Clearbridge Investments LLC lifted its holdings in Celgene Corporation by 24.1% in the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after acquiring an additional 892,392 shares during the period. State Street Corp lifted its holdings in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares during the period. Finally, Pioneer Investment Management Inc. lifted its holdings in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after acquiring an additional 710,584 shares during the period. 79.36% of the stock is owned by institutional investors.

In other news, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,233 shares of company stock worth $6,268,259. 0.95% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/11/celgene-corporation-celg-holdings-reduced-by-mitsubishi-ufj-kokusai-asset-management-co-ltd.html.

Shares of Celgene Corporation (NASDAQ:CELG) opened at 139.69 on Wednesday. The stock’s 50 day moving average price is $139.99 and its 200-day moving average price is $129.85. The stock has a market cap of $109.29 billion, a PE ratio of 43.26 and a beta of 1.88. Celgene Corporation has a one year low of $96.93 and a one year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.44 EPS. On average, equities analysts predict that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

A number of equities research analysts have commented on the company. Vetr raised Celgene Corporation from a “hold” rating to a “buy” rating and set a $146.58 target price for the company in a report on Friday, October 6th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $173.00 price target on shares of Celgene Corporation in a research note on Thursday, October 5th. Morgan Stanley downgraded Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research note on Thursday, October 5th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price target on shares of Celgene Corporation in a research note on Tuesday, September 26th. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $162.00 price target on shares of Celgene Corporation in a research note on Thursday, September 21st. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and twenty-two have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $150.60.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply